Sun Pharma Advanced Research Company Limited
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sun Pharma Advanced Research Company Limited sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Sun Pharma Advanced Research Company Limited: 20 sponsored US clinical trials, 1 recruiting.
Sun Pharma Advanced Research Company Limited sponsors 20 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 16 completed. 6 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Open Angle Glaucoma, with 2 trials.
Top-decile sponsor footprint
Sun Pharma Advanced Research Company Limited ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
NCT07042100
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
NCT02629692
A Study in Patients With Advanced Breast Cancer
NCT04942054
Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects
NCT04242953
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
NCT03655236
Evaluation of Efficacy and Safety of SDN-037
NCT03426267
Evaluation of Safety and Efficacy of PDP-716
NCT03450629
To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers
NCT03445338
Bioavailability Study of K0706 in Healthy Subjects
NCT03316820
Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
NCT02970019
Bioavailability Study of SPARC001 (Study 2) in Healthy Adult Volunteers
NCT02991261
Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers
NCT02991222
Study of SPARC1103 in Subjects With Spasticity
NCT02027025
Safety Study of SPARC1104
NCT01797185
Efficacy and Safety of SPARC0921 in Subjects With Spasticity
NCT01457352
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
NCT01305512
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
NCT01304303
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
NCT01320553
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
NCT00945958
Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension
NCT00947661
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 3 |
| Phase 3 | 6 |
What is open in the Sun Pharma Advanced Research Company Limited pipeline
1 recruiting of 20 indexed (5% open); 16 completed (80%).
Phase mix: 6 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Open Angle Glaucoma (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sun Pharma Advanced Research Company Limited: open-pipeline peers nationwide
Peers matched on 20 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Sun Pharma Advanced Research Company Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Avera McKennan Hospital & University Health Center · 5% recruiting · 20 trials
- HonorHealth Research Institute · 5% recruiting · 20 trials
- Integra LifeSciences Corporation · 5% recruiting · 60 trials
- Lumenis Be · 5% recruiting · 20 trials
Related
What to do with this Sun Pharma Advanced Research Company Limited page
20 registered trials is a research-attention snapshot, not an endorsement of Sun Pharma Advanced Research Company Limited or any single study.
- 1 of Sun Pharma Advanced Research Company Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Open Angle Glaucoma is the condition Sun Pharma Advanced Research Company Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Open Angle Glaucoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sun Pharma Advanced Research Company Limited pipeline card: 20 registered trials from official public datasets.Report a data error.